B+
Bull case
20%
Probability
Target price
$16.08
+26.7% vs current
CMPS
COMPASS PathwaysCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$8.17
-35.6% vs current
B-
Bear case
20%
Probability
Target price
$5.48
-56.8% vs current
AI sentiment snapshot
Latest data as of 2026-02-26
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+19.8
Score
AI commentary
Market tone is mixed-to-cautious with wide analyst target dispersion. Recent filings and prospectus activity increased near-term dilution concern; sentiment will remain event-driven around clinical/regulatory milestones.
RankAlpha Sentiment AI - 2026-02-26
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-27catalystAnalyst re-ratings / coverage updatesHigh impact
Near-term analyst target revisions or new coverage could widen or compress the trading range; aggregator snippets show wide dispersion.
2026-08-25eventLate-stage clinical / regulatory milestone (assumed)High impact
Binary COMP360 readout or regulatory milestone could sharply re-rate the stock; no firm public date so an assumed planning date is used (see valuation_check).
2027-02-26catalystCommercial / reimbursement progressHigh impact
Payer engagement, commercialization milestones, or a partnering deal would support multi-period re-rating; timeline and execution risk remain material.
Recommendation
N/A
No formal recommendation provided.
As of 2026-02-26 • Updated nightlySource: Internal modelMethodology